Comparing Predictive Oncology and Check-Cap Biotech Firms

Two small-cap medical device companies compete in the oncology space

Mar. 27, 2026 at 12:08am

Got story updates? Submit your updates here. ›

Predictive Oncology (NASDAQ:AGPU) and Check-Cap (NASDAQ:MBAI) are both small-cap manufacturing companies focused on oncology and medical diagnostics. This article compares the two firms across key metrics like analyst ratings, institutional ownership, valuation, profitability, and more to determine which stock is the better investment.

Why it matters

The oncology diagnostics and therapeutics market is highly competitive, with numerous small-cap firms vying for market share. Comparing the financial performance, growth potential, and competitive positioning of Predictive Oncology and Check-Cap can help investors make informed decisions about which company is better positioned to succeed in this dynamic industry.

The details

Check-Cap has a lower beta of 0.74, indicating its stock is less volatile than the broader market, while Predictive Oncology has a higher beta of 1.4. Predictive Oncology has higher revenue and earnings than Check-Cap, but Check-Cap trades at a lower price-to-earnings ratio, making it the more affordable of the two stocks currently. In terms of profitability, Predictive Oncology has higher net margins, return on equity, and return on assets compared to Check-Cap. Institutional ownership is also higher for Predictive Oncology at 9.0% versus 1.1% for Check-Cap.

  • The article was published on March 27, 2026.

The players

Check-Cap Ltd.

A clinical stage medical diagnostics company that develops a capsule-based screening technology using ultra-low-dose X-rays to detect precancerous polyps and other abnormalities in the colon.

Predictive Oncology Inc.

A knowledge-driven company focused on developing personalized cancer therapies using artificial intelligence, operating in four segments: Helomics, zPREDICTA, Soluble, and Skyline.

Got photos? Submit your photos here. ›

The takeaway

While both Predictive Oncology and Check-Cap are small-cap firms in the oncology diagnostics space, Predictive Oncology appears to have stronger financial performance, higher institutional backing, and potentially greater growth potential based on the comparative analysis. Investors should continue to monitor the competitive dynamics and execution of both companies as they vie for market share in this rapidly evolving industry.